Highlights

• Marksans Pharma will acquire 100% of Netherlands-based QliniQ B.V.
• QliniQ reported FY2025 revenue of EUR 9.35 million and net profit of EUR 1.01 million.
• The acquisition provides direct access to the Netherlands pharmaceutical market.

Marksans Pharma Limited (NSE:MARKSANS) announced that it has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a Netherlands-based pharmaceutical company engaged in the distribution and commercialization of pharmaceutical products and medical devices. The acquisition is aimed at expanding Marksans Pharma's presence across regulated European markets and strengthening its direct market access capabilities in the European Union.

The transaction will be completed through a cash consideration of EUR 7.5 million. According to the company, the acquisition is expected to be completed by June 15, 2026, or any other date agreed upon by the parties.

Source: Analysis by Kalkine 

QliniQ Brings Established Market Access Network

QliniQ operates across wholesaler, pharmacy, hospital and insurance-led tender channels in the Netherlands. The company markets niche pharmaceutical products and medical devices across women's health, dermatology, respiratory care, endocrinology and gastroenterology segments.

The company has established relationships with wholesalers, pharmacies, hospitals and health insurers in the Dutch healthcare ecosystem. It also operates EU GDP-compliant warehousing, wholesale distribution infrastructure and a direct-to-customer webshop.

For the financial year ended December 31, 2025, QliniQ reported revenue of EUR 9.35 million, profit before tax of EUR 1.34 million and net profit of EUR 1.01 million. The company had a net worth of EUR 1.45 million and reported no debt on its balance sheet.

Acquisition Expands European Footprint

According to Marksans Pharma, the acquisition will provide access to established sales, marketing and distribution capabilities in the Netherlands. The company stated that the transaction will enable it to utilize QliniQ's front-end infrastructure for marketing products manufactured in India, the United Kingdom and the United States.

The acquisition also offers participation in insurer-led tender channels, relationships with leading healthcare stakeholders and multiple routes to market through wholesalers, pharmacies and direct-to-consumer channels.

Commenting on the acquisition, Mark Saldanha, Chairman and Managing Director of Marksans Pharma, said:

"This acquisition represents an important strategic step in expanding Marksans’ presence across regulated European markets. QliniQ has built a profitable niche portfolio supported by established market access capabilities, long-standing customer relationships, and tender participation across the Netherlands healthcare ecosystem. The acquisition provides Marksans with direct access to the Netherlands market and enhances our ability to commercialize existing and future products across regulated European markets. We believe this acquisition will strengthen our long-term growth opportunities and further enhance our global business."

Share Performance

Marksans Pharma (NSE:MARKSANS) shares traded at INR 248.51 on June 1, 2026, up 0.94% from the previous close of INR 246.19. The stock opened at INR 249.00 and touched an intraday high of INR 256.00 and a low of INR 246.01. The volume-weighted average price (VWAP) stood at INR 250.94.

Source: Trading View

Key Risks

• Integration challenges may affect acquisition execution.
• European regulatory requirements could impact operations.
• Currency fluctuations may affect overseas earnings.
• Competition in specialty pharmaceutical markets remains high.

Summary

Marksans Pharma (NSE:MARKSANS) has agreed to acquire 100% of Netherlands-based QliniQ B.V. for EUR 7.5 million. QliniQ reported FY2025 revenue of EUR 9.35 million and net profit of EUR 1.01 million while maintaining a debt-free balance sheet. The acquisition provides Marksans with direct access to the Netherlands pharmaceutical market, established distribution capabilities and participation in healthcare tender channels across a regulated European market.

FAQs

Q: What company is Marksans Pharma acquiring?
A: Marksans Pharma is acquiring 100% of QliniQ B.V., a pharmaceutical and medical products company based in the Netherlands.

Q: What is the value of the acquisition?
A: Marksans Pharma will acquire QliniQ B.V. through a cash transaction valued at EUR 7.5 million.

Q: When is the acquisition expected to be completed?
A: The transaction is expected to be completed by June 15, 2026, subject to agreed closing conditions.